Alpha Tau Announces Robust Long-Term Safety and Efficacy Data from Multiple Clinical Trials of Alpha DaRT
August 17, 2023 17:00 ET
|
Alpha Tau Medical Ltd.
- 81 lesions treated across four feasibility trials of head and neck or skin cancers demonstrated 89% complete response rate. - Two-year local recurrence-free survival rate of 77%. - The analysis...
Alpha Tau Medical to Present at the Emerging Growth Conference on August 9th, 2023
August 02, 2023 09:00 ET
|
Alpha Tau Medical Ltd.
JERUSALEM, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™,...
Alpha Tau Medical to Participate in June Investor Conferences
May 24, 2023 16:01 ET
|
Alpha Tau Medical Ltd.
JERUSALEM, May 24, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™,...
Alpha Tau Medical Announces First Quarter 2023 Financial Results and Provides Corporate Update
May 23, 2023 16:01 ET
|
Alpha Tau Medical Ltd.
- Opened U.S. multicenter pivotal trial in recurrent cutaneous skin cancer, which began enrolling patients in March - - Treated the first patient with advanced inoperable pancreatic cancer in a...
Alpha Tau Expands its Alpha DaRT Treatment to Vulvar Cancer in Novel Clinical Trial with Cambridge University
May 17, 2023 16:30 ET
|
Alpha Tau Medical Ltd.
JERUSALEM, May 17, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™,...
Alpha Tau Announces the Publication of its US Multicenter Pilot Skin Cancer Trial Results in JAMA Network Open
May 11, 2023 16:00 ET
|
Alpha Tau Medical Ltd.
The trial demonstrated a 100% Complete Response rate at 12 weeks post treatment and no device-related serious adverse events or systemic toxicity reported in the 10 patients treated in the feasibility...
Alpha Tau Medical to Present at Guggenheim Radiopharmaceuticals Day
May 03, 2023 16:00 ET
|
Alpha Tau Medical Ltd.
JERUSALEM, May 03, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™,...
Alpha Tau and the JGH Announce Alpha DaRT Treatment of First Patient in its Advanced Pancreatic Cancer Clinical Trial
April 03, 2023 09:10 ET
|
Alpha Tau Medical Ltd.
JERUSALEM, April 03, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha...
Alpha Tau Medical to Present at Jefferies Radiopharma Innovation Summit
March 29, 2023 16:00 ET
|
Alpha Tau Medical Ltd.
JERUSALEM, March 29, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha...
Alpha Tau Medical Confirms No Direct Exposure to Silicon Valley Bank
March 12, 2023 08:30 ET
|
Alpha Tau Medical Ltd.
JERUSALEM, March 12, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha...